About Interstitial Cystitis and Bladder Pain Syndrome

Interstitial cystitis and bladder pain syndrome causes pain or discomfort related to the bladder with accompanying lower urinary tract symptoms such as urinary frequency, urgency, and the need to get up during the night to urinate.

Why Is This Study Important?

The treatment for interstitial cystitis and bladder pain syndrome can range from pain management, treatment directly into the bladder (called intravesical treatment), filling the bladder with water (hydrodistension) to see where bladder pain may be coming from, and using an electrical current to destroy any abnormal cells or tissues.

This study is being conducted to see if the study drug is safe and effective in treating the symptoms of women who have interstitial cystitis or bladder pain syndrome.

OAG1050 IC/BPS

Find Out More Today!

You may qualify for the OAG1050 study.

For more information about the OAG1050 study, contact a study team member at:

[Call Rhonda @ 501-954-7822

OAG1050 Recruitment Brochure_V2.0_08APR2022



Learn about the IC Bladder Pain study of a new investigational drug.

OAG1050 IC/BPS

About the OAG1050 Study

This study is testing a study drug that is designed to help alleviate the symptoms of interstitial cystitis and bladder pain syndrome. The study drug is a tablet taken once daily before bed.

Who Can Participate?

You may be able to join this study if you:

- Are a female between 18 and 64 years of age
- Have been diagnosed with interstitial cystitis or bladder pain syndrome
- Have bladder pain or discomfort with lower urinary tract symptoms for at least 6 months

There are other requirements for taking part in the OAG1050 study. The study team will discuss more criteria with you.

Why Participate?

If you qualify, you may receive at no cost access to the study drug, close care and monitoring of your condition, and the opportunity to help advance the treatment of interstitial cystitis and bladder pain syndrome. Reimbursement may be available for study-related time and travel expenses.

What to Expect

If you qualify and choose to participate, you will read and sign a consent form and receive a guide with more information about study visits.

Participation includes 2 phases:	
Pre-randomization Phase	
Screening/washout period	Up to 2 weeks
Study drug run-in period	2 weeks
Post-randomization Phase	
Treatment period • You will receive both study drug and placebo (an inactive substance that looks like the study drug) at different intervals during this period	8 weeks
End of treatment period	1 week
Follow-up period	1 week

Participation in the OAG1050 study lasts approximately 3.5 months and requires up to 9 visits to the study site and at least 4 phone calls.

What Is a Clinical Research Study?

A clinical research study is carefully supervised research that is done before a study drug is made available to the public. Clinical research studies follow government regulations that help protect the safety and rights of study participants.

Participation is completely voluntary, and study doctors discuss all study details with their patients before entry into the study. These details include information about the study medication, what happens during the study, and any potential risks or side effects.

Doctors and scientists perform clinical research studies to:

- Evaluate the safety and effectiveness of study drugs or devices
- Answer specific health questions
- Discover new ways to improve patient health

OAG1050
IC/BPS